Northside Hospital, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1970-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.northside.com
Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Phase 2
Completed
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02771197
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Phase 2
Completed
- Conditions
- MyelofibrosisMultiple MyelomaMyelodysplastic SyndromeNon-Hodgkin's LymphomaAcute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaCMMLChronic Myelogenous LeukemiaHodgkin's LymphomaAcute Myelogenous Leukemia
- Interventions
- Procedure: peripheral blood stem cell transplant
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT02581007
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma
Phase 2
Completed
- Conditions
- Multiple Myeloma
- Interventions
- Drug: BeEAM
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT02416206
- Locations
- 🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Phase 2
Completed
- Conditions
- Acute LeukemiaLymphomasChronic LeukemiaMultiple MyelomaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT02169791
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
MOSTEGRA TRIAL:MO-(Dified) STE-(nt) GRA(-ft): Surgeon-modified Fenestrated-branched Stent-grafts
Not Applicable
Terminated
- Conditions
- Complex Aortic Aneurysms
- Interventions
- Device: surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT02101463
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
Phase 2
Completed
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT01370408
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases
Phase 2
Completed
- Conditions
- Non-Hodgkin's LymphomaMyelodysplastic SyndromeAcute LeukemiaHodgkin's DiseaseChronic Leukemia
- Interventions
- Procedure: Peripheral Blood Stem Cell Transplant
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01336712
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Not Applicable
Completed
- Conditions
- Pulmonary Infiltrate New
- Interventions
- Other: Microbiological analysis
- First Posted Date
- 2011-04-05
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT01328873
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
Phase 2
Completed
- Conditions
- Hematologic Neoplasms
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01244906
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01161628
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
© Copyright 2025. All Rights Reserved by MedPath